The ESPRIT trial will examine the efficacy and safety of adding Epanova to statin therapy for patients with very high triglycerides.
Epanova, an omega-3 prescription drug in trial targeting patients with very high triglycerides, has enrolled the first patient for its ESPRIT Phase III clinical trial. The announcement was made by drug’s developer, Omthera Pharmaceuticals.
The ESPRIT trial will be a six-week, randomized, double-blind, placebo-controlled, parallel group study that will examine the efficacy and safety of adding Epanova to statin therapy for patients with very high triglycerides (between 200 and 500 mg/dL). It will enroll 642 subjects across approximately 100 sites in the United States.
Epanova is a novel formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) omega-3 fatty acids. Ultimately, it is aimed at patients with very high triglycerides greater than or equal to 500 mg/dL. The company says that as a free fatty acid form of EPA and DHA, as opposed to the ethyl ester form, Epanova offers superior bioavailability compared to other prescription omega-3 drugs, such as Lovaza.
Epanova is also in a Phase III trial currently being conducted, called EVOLVE, and Omthera plans to file a new drug application for Epanova.
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.